Ann: Ilara and ResApp Announce Evaluation of ResAppDx in Africa, page-33

This is the type of steady news flow that we need. As pointed out by others here, there's nothing to lose and everything to gain.

Given the lack of access to xray / pathology tests in Africa, ResAppDx uptake should surprise on the upside. (As there's little alternative, and much cheaper, even in places where there's access). As such, I wouldn't be surprised that ResAppDx may end up being able to charge the $5-$10 it wants to, even in Africa. But let's say if it doesn't achieve the $5-$10, say just $1 per use, if uptake is high enough, that would still highly significant revenue IMO.

Even in the worst case scenario, that ResAppDx does it for free let's say, it would still be hugely beneficial on many fronts:

1) Widespread "charitable" usage would put ResAppDx on newspaper and on social media. "Solving the pneumonial crisis and saving children in Africa". Imagine the huge publicity for ResAppDx!
2) Additional data to support real world efficacy and cost-benefits.
3) Additional cough data (COVID19 signature?) - Remember Australia is not a great place to do trials for COVID19 because of a lack of cases. Africa would be much better

Very exciting